| Dr Eric C Robinson, MD | |
|
2700 Dolbeer St, Eureka, CA 95501-4736 | |
| (707) 445-8121 | |
| Not Available |
| Full Name | Dr Eric C Robinson |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 12 Years |
| Location | 2700 Dolbeer St, Eureka, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497017339 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 140384 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Presbyterian Hospital | Albuquerque, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Presbyterian Healthcare Services | 9234041708 | 1099 |
News Archive
As psychedelics gain ground as a potential therapy for mental health disorders, there remains a pressing concern that patients in clinical trials may have adverse effects to the drugs.
Boston University researchers have learned new information about the consequences of overeating high-calorie foods. Not only does this lead to an increase in white fat cell production, the type prominent in obesity, but it also leads to the dysfunction of brown fat cells, the unique type of fat that generates heat and burns energy.
Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).
The Food and Drug Administration is preparing to enact provisions of the new food-safety bill that was passed by Congress in the waning days of 2010 and is expected to be signed into law Tuesday (Tomson, 1/4).
› Verified 9 days ago
| Entity Name | Presbyterian Healthcare Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104802354 PECOS PAC ID: 9234041708 Enrollment ID: O20031103000603 |
News Archive
As psychedelics gain ground as a potential therapy for mental health disorders, there remains a pressing concern that patients in clinical trials may have adverse effects to the drugs.
Boston University researchers have learned new information about the consequences of overeating high-calorie foods. Not only does this lead to an increase in white fat cell production, the type prominent in obesity, but it also leads to the dysfunction of brown fat cells, the unique type of fat that generates heat and burns energy.
Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).
The Food and Drug Administration is preparing to enact provisions of the new food-safety bill that was passed by Congress in the waning days of 2010 and is expected to be signed into law Tuesday (Tomson, 1/4).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric C Robinson, MD Po Box 26666, Phs Provider Enrollment, Albuquerque, NM 87125-6666 Ph: (505) 923-6770 | Dr Eric C Robinson, MD 2700 Dolbeer St, Eureka, CA 95501-4736 Ph: (707) 445-8121 |
News Archive
As psychedelics gain ground as a potential therapy for mental health disorders, there remains a pressing concern that patients in clinical trials may have adverse effects to the drugs.
Boston University researchers have learned new information about the consequences of overeating high-calorie foods. Not only does this lead to an increase in white fat cell production, the type prominent in obesity, but it also leads to the dysfunction of brown fat cells, the unique type of fat that generates heat and burns energy.
Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).
The Food and Drug Administration is preparing to enact provisions of the new food-safety bill that was passed by Congress in the waning days of 2010 and is expected to be signed into law Tuesday (Tomson, 1/4).
› Verified 9 days ago
Eric Gerdes, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2700 Dolbeer St, Eureka, CA 95501 Phone: 707-269-4250 | |
Paul Windham, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1915 Harrison Ave Ste A, Eureka, CA 95501 Phone: 707-497-6342 Fax: 707-497-6234 | |
Marcelle Mahan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2700 Dolbeer St, Eureka, CA 95501 Phone: 707-269-4250 | |
Joseph B. Burkes, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 714 F St, Eureka, CA 95501 Phone: 707-442-5335 Fax: 707-442-1452 | |
Dr. Deonnae Lopez, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2700 Dolbeer St, Eureka, CA 95501 Phone: 707-269-4250 | |
Alan Morden, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2700 Dolbeer St, Eureka, CA 95501 Phone: 707-445-8121 Fax: 707-269-3753 | |
Tuan Luu, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2700 Dolbeer St, Eureka, CA 95501 Phone: 707-269-4250 |